Loading...
Loading...
SLGL| Name | Value |
|---|---|
| Revenues | 466.0K |
| Cost of Revenue | 5,345.0K |
| Gross Profit | -4,879.0K |
| Operating Expense | 7,178.0K |
| Operating I/L | -6,712.0K |
| Other Income/Expense | 368.0K |
| Interest Income | 368.0K |
| Pretax | -6,344.0K |
| Income Tax Expense | -85.5K |
| Net Income/Loss | -6,344.0K |
Sol-Gel Technologies Ltd. is a clinical stage specialty pharmaceutical company based in Israel. The company focuses on developing and commercializing topical dermatological drug products using its proprietary microencapsulation delivery system. Its lead product candidates include Twyneo, a once-daily topical cream for acne vulgaris, and Epsolay for papulopustular rosacea. Additionally, the company is involved in the development of generic topical dermatological drug products. Sol-Gel Technologies generates revenue through the sale and commercialization of its proprietary drug products, as well as through collaborations with partners such as Perrigo for the distribution and marketing of its products.
